WDNA: Tap into the BioRevolution That’s Transforming Our World

If the 19th century was the century of chemistry and the 20th the century of physics, we believe the 21st will be the century of biology.

As we unravel secrets about DNA and deploy that knowledge to re-engineer biological systems, we believe revolutionary advances will continually transform industries from healthcare, agriculture and manufacturing to energy production, consumer services and data storage creating a historic investment opportunity. To help investors capitalize, we leveraged the insights of futurist Jamie Metzl, member of the World Health Organization’s expert committee on human genome editing, to launch a revolutionary new ETF, the WisdomTree BioRevolution Fund (WDNA).

RESOURCES

The Case for WisdomTree BioRevolution Fund (WDNA)

Presentation: WisdomTree BioRevolution Fund

Next Big Thing Podcast

WisdomTree U.S. Thematic Update

View our other MEGATRENDS strategies

Invest in the Power of Innovation

The biology revolution is rapidly improving our ability to understand, read, write, and hack DNA, the genetic code of all life. Learn how the WisdomTree BioRevolution Fund (WDNA) can help capitalize on this megatrend.

Why WisdomTree Believes the BioRevolution Could Deliver Strongly in 2024

In this Office Hours replay, Global Head of Research Chris Gannatti is joined by Jamie Metzl, Founder and Chair of OneShared.World for an in-depth discussion regarding the extended period of very challenging returns within the broader equity market, and how we believe the tide could turn in 2024 across the Biotechnology landscape.

 

Can We Predict the Future of Our Species?

Jamie Metzl (2022)

In an insightful panel, Dubai Future Forum welcomed Dr. Jamie Metzl, Founder and Chair, OneShared.World, where he discussed the three essential steps that lead to imagining the future of our species. WisdomTree partnered with Jamie to shape the WisdomTree BioRevolution Fund (WDNA).

Are You Ready for the Genetic Revolution?

Jamie Metzl (TEDxPaloAlto)

DNA sequencing is at the core of the BioRevolution. In this thought-provoking TED Talk, renowned futurist and thought leader on the BioRevolution, Jamie Metzl, breaks down the how’s, why’s and what-if’s of the genetic revolution that is transforming this century. WisdomTree partnered with Jamie to shape the new WisdomTree BioRevolution Fund (WDNA).

Statements concerning trends in the fields, industries and sectors discussed are based on current conditions, which will fluctuate. References to specific securities and their issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. This material represents an assessment of trends discussed at a specific time and is not intended to be a forecast of future events or a guarantee of future results. This material should not be relied upon as research or investment advice regarding any security in particular. The user of this information assumes the entire risk of any use made of the information provided herein.

Bloomberg Businessweek Podcast:
Investing in the BioRevolution Megatrend

Jeremy Schwartz, Global Head of Research at Wisdomtree and Jamie Metzl, Senior Fellow at the Atlantic Council, discuss launching their BioRevolution Fund to invest in multiple fields including vaccines, agriculture and big data analytics.

 

For a list of Fund holdings, visit WDNA Fund detail page.

Our BioRevolution Fund

WDNA
WisdomTree BioRevolution Fund
The WisdomTree BioRevolution Fund (WDNA) provides targeted exposure to companies that have the potential to be significantly transformed by advancements in genetics and biotechnology.
Learn more about WDNA

Commentaries from Our Thought Leaders

Why We Loved Bill Gates’s Annual Letter
by Christopher Gannatti, CFA
Bill Gates recently posed five questions about AI and its potential to improve innovation in healthcare in his annual letter. Christopher Gannatti takes a look at each question and then highlights a WisdomTree strategy that focuses on the biotechnology sphere.
Read the blog post
When Multiple Megatrends Collide, Lives Might Be Saved
by Christopher Gannatti, CFA
The technologies of the AI, genetics and biotechnology revolutions tend to overlap, continuously accelerating innovation and impact. These impacts are being seen in many different sectors, including Health Care. Christopher Gannatti highlights an example of how megatrends can collide.
Read the blog post
Is it Time for Biotech?
by Christopher Gannatti, CFA
Biotech stocks have been underperforming for three years, but could a recent breakthrough in CRISPR therapy change the tide? Christopher Gannatti explores potential opportunities and how to invest. 
Read the blog post
    For more daily insights from our thought leaders, visit our blog.